Nuclera and University of Cambridge Researchers Demonstrate Rapid Structural Analysis of Challenging Drug Target

CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)–Nuclera, the biotechnology company enabling access to innovative protein technologies, today announced the publication of research conducted in collaboration with researchers at the University of Cambridge’s Department of Biochemistry, demonstrating a rapid, cell-free approach utilizing proprietary nanodisc technology to produce challenging protein drug-targets for high-resolution structural analysis.The research, published as a preprint on bioRxiv,

Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.